Skip to main content
Grant Details

Grant Number: 5R50CA211115-03 Interpret this number
Primary Investigator: Bowles, Erin
Organization: Kaiser Foundation Research Institute
Project Title: Group Health Cancer Research Program Research Specialist Award
Fiscal Year: 2018
Back to top


Abstract

Project Summary/Abstract The goal of this application is to support Erin Bowles, MPH, as a Senior Research Associate at Group Health Research Institute. She supports the Cancer Research Group on multiple NCI-funded projects under the direction of Diana Buist, PhD. Ms. Bowles is an accomplished epidemiologic cancer scientist in areas such as breast cancer screening and treatment. Her work is primarily funded by the National Cancer Institute. Group Health is a learning healthcare system, giving her work the potential to be translated and disseminated into clinical practice. This Research Specialist Award would provide her with 5 years of funding during which she would commit to working on NCI-funded projects such as the Breast Cancer Surveillance Consortium and Cancer Research Network. These projects have had measurable impacts on healthcare and health outcomes in the US, such as contributing to national breast cancer screening guideline development and providing population-based estimates of cancer treatment outcomes beyond results from clinical trials. On these projects, Ms. Bowles will fill various roles including site PI, project/data manager, clinical liaison, mammographic density reader, statistical analyst, grant writer, publication author, and cancer epidemiologist. She will actively work to ensure project results are broadly disseminated to clinical practice.

Back to top


Publications

Trends in Use of Medical Imaging in US Health Care Systems and in Ontario, Canada, 2000-2016.
Authors: Smith-Bindman R. , Kwan M.L. , Marlow E.C. , Theis M.K. , Bolch W. , Cheng S.Y. , Bowles E.J.A. , Duncan J.R. , Greenlee R.T. , Kushi L.H. , et al. .
Source: JAMA, 2019-09-03; 322(9), p. 843-856.
PMID: 31479136
Related Citations

Risk of second breast cancer events with chronic opioid use in breast cancer survivors.
Authors: Boudreau D.M. , Chen L. , Yu O. , Bowles E.J.A. , Chubak J. .
Source: Pharmacoepidemiology and drug safety, 2019 May; 28(5), p. 740-753.
EPub date: 2019-04-03.
PMID: 30945381
Related Citations

Use of antidepressants after colon cancer diagnosis and risk of recurrence.
Authors: Pocobelli G. , Yu O. , Ziebell R.A. , Aiello Bowles E.J. , Fujii M.M. , Sterrett A.T. , Boggs J.M. , Chen L. , Boudreau D.M. , Ritzwoller D.P. , et al. .
Source: Psycho-oncology, 2019 Apr; 28(4), p. 750-758.
EPub date: 2019-02-14.
PMID: 30703275
Related Citations

Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study.
Authors: Bowles E.J.A. , Yu O. , Ziebell R. , Chen L. , Boudreau D.M. , Ritzwoller D.P. , Hubbard R.A. , Boggs J.M. , Burnett-Hartman A.N. , Sterrett A. , et al. .
Source: BMC cancer, 2019-03-27; 19(1), p. 270.
EPub date: 2019-03-27.
PMID: 30917783
Related Citations

Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium.
Authors: Sprague B.L. , Kerlikowske K. , Bowles E.J.A. , Rauscher G.H. , Lee C.I. , Tosteson A.N.A. , Miglioretti D.L. .
Source: Journal of the National Cancer Institute, 2019-01-08; , .
EPub date: 2019-01-08.
PMID: 30624682
Related Citations

Risk of colon cancer recurrence in relation to diabetes.
Authors: Chubak J. , Yu O. , Ziebell R.A. , Bowles E.J.A. , Sterrett A.T. , Fujii M.M. , Boggs J.M. , Burnett-Hartman A.N. , Boudreau D.M. , Chen L. , et al. .
Source: Cancer causes & control : CCC, 2018 Nov; 29(11), p. 1093-1103.
EPub date: 2018-09-22.
PMID: 30244297
Related Citations

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density.
Authors: Brentnall A.R. , Cuzick J. , Buist D.S.M. , Bowles E.J.A. .
Source: JAMA oncology, 2018-09-01; 4(9), p. e180174.
EPub date: 2018-09-13.
PMID: 29621362
Related Citations

Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative.
Authors: Pinto H.A. , McCaskill-Stevens W. , Wolfe P. , Marcus A.C. .
Source: Annals of epidemiology, 2000 Nov; 10(8 Suppl), p. S78-84.
PMID: 11189096
Related Citations

High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Authors: Hines J.D. , Oken M.M. , Mazza J.J. , Keller A.M. , Streeter R.R. , Glick J.H. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984 Jun; 2(6), p. 545-9.
PMID: 6233399
Related Citations




Back to Top